- Home
- SRAD vs JAZZ Comparison
SRAD vs JAZZ Comparison
Compare SRAD & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRAD
- JAZZ
- Stock Information
- Founded
- SRAD 2001
- JAZZ 2003
- Country
- SRAD Switzerland
- JAZZ Ireland
- Employees
- SRAD N/A
- JAZZ N/A
- Industry
- SRAD Computer Software: Programming Data Processing
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- SRAD Technology
- JAZZ Health Care
- Exchange
- SRAD Nasdaq
- JAZZ Nasdaq
- Market Cap
- SRAD 9.0B
- JAZZ 8.2B
- IPO Year
- SRAD 2021
- JAZZ 2007
- Fundamental
- Price
- SRAD $26.23
- JAZZ $136.93
- Analyst Decision
- SRAD Strong Buy
- JAZZ Strong Buy
- Analyst Count
- SRAD 17
- JAZZ 14
- Target Price
- SRAD $30.59
- JAZZ $179.43
- AVG Volume (30 Days)
- SRAD 2.5M
- JAZZ 649.4K
- Earning Date
- SRAD 11-05-2025
- JAZZ 11-05-2025
- Dividend Yield
- SRAD N/A
- JAZZ N/A
- EPS Growth
- SRAD 359.43
- JAZZ N/A
- EPS
- SRAD 0.43
- JAZZ N/A
- Revenue
- SRAD $1,399,017,029.00
- JAZZ $4,086,695,000.00
- Revenue This Year
- SRAD $19.11
- JAZZ $5.75
- Revenue Next Year
- SRAD $16.77
- JAZZ $6.09
- P/E Ratio
- SRAD $61.54
- JAZZ N/A
- Revenue Growth
- SRAD 19.37
- JAZZ 4.52
- 52 Week Low
- SRAD $12.26
- JAZZ $95.49
- 52 Week High
- SRAD $32.22
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- SRAD 42.40
- JAZZ 55.63
- Support Level
- SRAD $26.70
- JAZZ $136.38
- Resistance Level
- SRAD $27.85
- JAZZ $140.00
- Average True Range (ATR)
- SRAD 1.01
- JAZZ 3.01
- MACD
- SRAD 0.16
- JAZZ -0.32
- Stochastic Oscillator
- SRAD 56.67
- JAZZ 59.54
About SRAD Sportradar Group AG
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.